ALKEM LABS: REVENUE UP 14%, BUT PROFIT DECLINES 12%! 💊

ALKEM Growth in sales, but why is the bottom line under pressure? Alkem Laboratories has announced its Q2 FY27 consolidated results. Key financial highlights: Revenue: ₹4,552 crore, up 13.8% YoY. EBITDA: ₹1,025 crore, up 11.3% YoY. EBITDA margin: 22.5% versus 23% last year. Net profit: ₹675 crore, down 11.7% YoY. India sales: ₹3,027.5 crore, up 9.5%. International sales: ₹1,454 crore, up 22.3%. Why this matters: The company delivered healthy revenue growth, but net profit declined. Higher research and development expenses and the tax impact are important factors to examine. What to monitor next: India pharmaceutical sales US business growth and pricing pressure EBITDA margin movement R&D expenditure Biotech and MedTech business performance My analytical view: The quarter is mixed. Revenue and operating earnings improved, but shareholders need to understand why net profit declined despite higher sales. The international business and margin trajectory deserve attention. Disclosure: State your actual holding or interest, if any, before publishing. SEBI RA Disclaimer: Umang Rajesh Bhutada is a SEBI-registered Research Analyst (INH000023001). This content is for educational and informational purposes only and is not investment advice. Securities investments are subject to market risks. Please consult a qualified financial professional before making investment decisions.